SEP Analytical (Shanghai) Balance Sheet Health
Financial Health criteria checks 6/6
SEP Analytical (Shanghai) has a total shareholder equity of CN¥807.7M and total debt of CN¥57.7M, which brings its debt-to-equity ratio to 7.1%. Its total assets and total liabilities are CN¥1.2B and CN¥353.4M respectively.
Key information
7.1%
Debt to equity ratio
CN¥57.67m
Debt
Interest coverage ratio | n/a |
Cash | CN¥307.29m |
Equity | CN¥807.73m |
Total liabilities | CN¥353.41m |
Total assets | CN¥1.16b |
Recent financial health updates
No updates
Recent updates
Subdued Growth No Barrier To SEP Analytical (Shanghai) Co., Ltd. (SZSE:301228) With Shares Advancing 29%
Dec 18Revenues Not Telling The Story For SEP Analytical (Shanghai) Co., Ltd. (SZSE:301228) After Shares Rise 31%
Sep 30SEP Analytical (Shanghai) Co., Ltd.'s (SZSE:301228) 27% Share Price Plunge Could Signal Some Risk
Aug 09Some Confidence Is Lacking In SEP Analytical (Shanghai) Co., Ltd. (SZSE:301228) As Shares Slide 31%
May 05More Unpleasant Surprises Could Be In Store For SEP Analytical (Shanghai) Co., Ltd.'s (SZSE:301228) Shares After Tumbling 26%
Feb 26Financial Position Analysis
Short Term Liabilities: 301228's short term assets (CN¥901.4M) exceed its short term liabilities (CN¥325.7M).
Long Term Liabilities: 301228's short term assets (CN¥901.4M) exceed its long term liabilities (CN¥27.7M).
Debt to Equity History and Analysis
Debt Level: 301228 has more cash than its total debt.
Reducing Debt: 301228's debt to equity ratio has reduced from 12.6% to 7.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 301228 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 301228 is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 4.3% per year.
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/07 10:00 |
End of Day Share Price | 2025/01/07 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SEP Analytical (Shanghai) Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|